Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.

导出 OA

翻译打印收藏纠错

第一作者： Steffen,Koschmieder

第一单位： Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.

作者： Steffen,Koschmieder ^[1] ; Edgar,Jost ^[1] ; Christian,Cornelissen ^[2] ; Tobias,Müller ^[2] ; Maximilian,Schulze-Hagen ^[3] ; Johannes,Bickenbach ^[4] ; Gernot,Marx ^[4] ; Michael,Kleines ^[5] ; Nikolaus,Marx ^[6] ; Tim H,Brümmendorf ^[1] ; Michael,Dreher ^[2]

作者单位： Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. ^[1] Department of Pneumology and Intensive Care Medicine, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. ^[2] Department of Diagnostic and Interventional Radiology, RWTH Aachen University, Aachen, Germany. ^[3] Department of Intensive Care and Intermediate Care, RWTH Aachen University, Aachen, Germany. ^[4] Labordiagnostisches Zentrum &, Department of Medical Microbiology, RWTH Aachen University, Aachen, Germany. ^[5] Clinic for Cardiology, Angiology and Internal Intensive Medicine, Medical Clinic I, RWTH Aachen University, Aachen, Germany. ^[6]

关键词 COVID-19 cytokine storm mild course primary myelofibrosis ruxolitinib